Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

(2018) Gerrit J. Schuurhuis et al.   BLOOD

BCL-2 inhibition in AML: an unexpected bonus?

(2018) Marina Konopleva et al.   BLOOD

Pathways and mechanisms of venetoclax resistance

(2017) Prithviraj Bose et al.   LEUKEMIA & LYMPHOMA

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia

(2016) K. H. Metzeler et al.   BLOOD

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

(2016) M. Konopleva et al.   Cancer Discovery

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

(2015) H. Dombret et al.   BLOOD

The prognostic relevance of flt3 and npm1 mutations on older patients treated intensively or non-intensively: a study of 1312 patients in the UK NCRI AML16 trial

(2014) M Lazenby et al.   LEUKEMIA

Ex vivoactivity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies

(2014) James M. Bogenberger et al.   LEUKEMIA & LYMPHOMA

Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia

(2013) Sylvie D. Freeman et al.   JOURNAL OF CLINICAL ONCOLOGY

Concise Drug Review: Azacitidine and Decitabine

(2013) E. J. B. Derissen et al.   ONCOLOGIST

Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

(2013) R. Pan et al.   Cancer Discovery

Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells

(2012) Twee Tsao et al.   ANNALS OF HEMATOLOGY

Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML

(2012) Thanh-Trang Vo et al.   CELL

Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia

(2012) Hiroto Inaba et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2012) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

(2012) Jay P. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

The prognostic significance of IDH2 mutations in AML depends on the location of the mutation

(2011) C. L. Green et al.   BLOOD

TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome

(2011) F. G. Rucker et al.   BLOOD

Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study

(2011) Haifa K. Al-Ali et al.   LEUKEMIA & LYMPHOMA

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

(2010) H. Kantarjian et al.   BLOOD

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia

(2009) Amanda F. Cashen et al.   JOURNAL OF CLINICAL ONCOLOGY